

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH MIGRAINE

1. Ailani J, Burch RC, Robbins MS: **The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.** *Headache* 2021, **61**(7):1021-1039.
2. Ha H, Gonzalez A: **Migraine Headache Prophylaxis.** *Am Fam Physician* 2019, **99**(1):17-24.
3. Parikh SK, Silberstein SD: **Preventive Treatment for Episodic Migraine.** *Neurol Clin* 2019, **37**(4):753-770.
4. Department of Veterans Affairs/Department of Defense: **VA/DoD Clinical Practice Guideline for the Primary Care Management of Headache.** In.; 2020.
5. Martin VT, Feoktistov A, Solomon GD: **A rational approach to migraine diagnosis and management in primary care.** *Ann Med* 2021, **53**(1):1979-1990.
6. Loder E, Burch R, Rizzoli P: **The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines.** *Headache* 2012, **52**(6):930-945.
7. Pringsheim T, Davenport W, Mackie G, Worthington I, Aube M, Christie SN, Gladstone J, Becker WJ: **Canadian Headache Society guideline for migraine prophylaxis.** *The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques* 2012, **39**(2 Suppl 2):S1-59.
8. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, Group T-M-S: **Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.** *Cephalalgia : an international journal of headache* 2007, **27**(7):814-823.
9. Mei D, Ferraro D, Zelano G, Capuano A, Vollono C, Gabriele C, Di Trapani G: **Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine.** *Clinical neuropharmacology* 2006, **29**(5):269-275.
10. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E: **Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.** *Neurology* 2012, **78**(17):1337-1345.
11. Toward Optimized Practice (TOP) Program: **Guideline for Primary Care Management of Headache in Adults.** In. Alberta, Canada: Institute of Health Economics; 2016.

12. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor PS: **EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.** *European journal of neurology* 2009, **16**(9):968-981.
13. NICE: **Summary of selected new evidence: Headaches.** 2012, with update October 2014.
14. NICE: **Headaches in over 12s: diagnosis and management.** September 2012.
15. Mulleners WM, McCrory DC, Linde M: **Antiepileptics in migraine prophylaxis: an updated Cochrane review.** *Cephalalgia : an international journal of headache* 2015, **35**(1):51-62.
16. He A, Song D, Zhang L, Li C: **Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis.** *The journal of headache and pain* 2017, **18**(1):26.
17. NICE: **Diagnosis and management of headaches in young people and adults.** . 2012.
18. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E: **Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.** *Neurology* 2012, **78**(17):1346-1353.
19. Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M, Berbano E, O'Malley PG: **Tricyclic antidepressants and headaches: systematic review and meta-analysis.** *BMJ (Clinical research ed)* 2010, **341**:c5222.
20. Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J: **A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache.** *PLoS one* 2015, **10**(7):e0130733.
21. Prophylaxis) NM: **Migraine Prophylaxis: Flunarizine.** Sept 2014.
22. NICE: **Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. NICE technology appraisal guidance** June 2012.
23. Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS, Jabbari B, Kaufmann HC, Schurch B, Silberstein SD *et al*: **Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.** *Neurology* 2008, **70**(19):1707-1714.
24. Silberstein SD, Elkind AH, Schreiber C, Keywood C: **A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.** *Neurology* 2004, **63**(2):261-269.

25. UpToDate (Bajwa ZH SJ: **Preventive treatment of migraine in adults.** . In. Ipswich, MA: EBSCO Information Services; 2015.
26. Peroutka SJ: **What turns on a migraine? A systematic review of migraine precipitating factors.** *Current pain and headache reports* 2014, **18**(10):454.
27. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL: **Migraine prophylaxis with divalproex.** *Archives of neurology* 1995, **52**(3):281-286.
28. Klapper J: **Divalproex sodium in migraine prophylaxis: a dose-controlled study.** *Cephalalgia : an international journal of headache* 1997, **17**(2):103-108.
29. Freitag FG, Collins SD, Carlson HA, Goldstein J, Saper J, Silberstein S, Mathew N, Winner PK, Deaton R, Sommerville K *et al*: **A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.** *Neurology* 2002, **58**(11):1652-1659.
30. Hering R, Kuritzky A: **Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo.** *Cephalalgia : an international journal of headache* 1992, **12**(2):81-84.
31. Jensen R, Brinck T, Olesen J: **Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study.** *Neurology* 1994, **44**(4):647-651.
32. Linde M, Mulleners WM, Chronicle EP, McCrory DC: **Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults.** *The Cochrane database of systematic reviews* 2013(6):Cd010611.
33. Kaniecki RG: **A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura.** *Archives of neurology* 1997, **54**(9):1141-1145.
34. Afshari D, Rafizadeh S, Rezaei M: **A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis.** *The International journal of neuroscience* 2012, **122**(2):60-68.
35. Kinze S, Clauss M, Reuter U, Wolf T, Dreier JP, Einhaupl KM, Arnold G: **Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study.** *Headache* 2001, **41**(8):774-778.
36. Mitsikostas DD, Polychronidis I: **Valproate versus flunarizine in migraine prophylaxis: a randomized, double-open, clinical trial.** *Functional neurology* 1997, **12**(5):267-276.
37. Kalita J, Bhoi SK, Misra UK: **Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial.** *Acta neurologica Scandinavica* 2013, **128**(1):65-72.

38. Krymchantowski AV, Jevoux CC: **Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study.** *Headache* 2011, **51**(4):554-558.
39. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmitt J, Neto W, Schwabe S, Jacobs D, Group M-S: **Topiramate for migraine prevention: a randomized controlled trial.** *Jama* 2004, **291**(8):965-973.
40. Silberstein SD, Neto W, Schmitt J, Jacobs D, Group M-S: **Topiramate in migraine prevention: results of a large controlled trial.** *Archives of neurology* 2004, **61**(4):490-495.
41. Diener HC, Tfelt-Hansen P, Dahlof C, Lainez MJ, Sandrini G, Wang SJ, Neto W, Vijapurkar U, Doyle A, Jacobs D *et al*: **Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control.** *Journal of neurology* 2004, **251**(8):943-950.
42. Mei D, Capuano A, Vollono C, Evangelista M, Ferraro D, Tonali P, Di Trapani G: **Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study.** *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology* 2004, **25**(5):245-250.
43. Silberstein SD, Hulihan J, Karim MR, Wu SC, Jordan D, Karvois D, Kamin M: **Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study.** *Clinical therapeutics* 2006, **28**(7):1002-1011.
44. Storey JR, Calder CS, Hart DE, Potter DL: **Topiramate in migraine prevention: a double-blind, placebo-controlled study.** *Headache* 2001, **41**(10):968-975.
45. Ashtari F, Shaygannejad V, Akbari M: **A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis.** *Acta neurologica Scandinavica* 2008, **118**(5):301-305.
46. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V: **Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study.** *Headache* 2006, **46**(4):642-648.
47. Gupta P, Singh S, Goyal V, Shukla G, Behari M: **Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study).** *Headache* 2007, **47**(3):402-412.
48. de Tommaso M, Marinazzo D, Nitti L, Pellicoro M, Guido M, Serpino C, Stramaglia S: **Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine.** *Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology* 2007, **118**(10):2297-2304.
49. Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, Ertas M, Lanteri-Minet M, Reuter U, Sanchez Del Rio M *et al*: **Cessation versus continuation of 6-month migraine**

preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. *The Lancet Neurology* 2007, **6**(12):1054-1062.

50. Edwards KR, Glantz M, Norton J, Cross N: **Prophylactic treatment of episodic migraine with topiramate: a double-blind, placebo-controlled trial in 30 patients.** *Cephalalgia : an international journal of headache* 2000, **20**(4):316.
51. Lipton RB, Silberstein S, Dodick D, Cady R, Freitag F, Mathew N, Biondi DM, Ascher S, Olson WH, Hulihan J: **Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study.** *Cephalalgia : an international journal of headache* 2011, **31**(1):18-30.
52. Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, Biondi D, Greenberg SJ, Hulihan J, Group C-I: **Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.** *Clinical therapeutics* 2009, **31**(3):542-559.
53. Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R: **The efficacy and safety of venlafaxine in the prophylaxis of migraine.** *Headache* 2005, **45**(2):144-152.
54. Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B: **Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study.** *Clinical neurology and neurosurgery* 2004, **107**(1):44-48.
55. Linde K, Rosznagel K: **Propranolol for migraine prophylaxis.** *The Cochrane Library* 2004.
56. Tfelt-Hansen P, Standnes B, Kangasneimi P, Hakkarainen H, Olesen J: **Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial.** *Acta neurologica Scandinavica* 1984, **69**(1):1-8.
57. Stellar S, Ahrens SP, Meibohm AR, Reines SA: **Migraine prevention with timolol. A double-blind crossover study.** *Jama* 1984, **252**(18):2576-2580.
58. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G: **Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study.** *BMJ (Clinical research ed)* 2001, **322**(7277):19-22.
59. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G: **Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.** *Jama* 2003, **289**(1):65-69.
60. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, Group PCMS: **OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.** *Cephalalgia : an international journal of headache* 2010, **30**(7):793-803.

61. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, Group PCMS: **OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.** *Cephalalgia : an international journal of headache* 2010, **30**(7):804-814.
62. Medicines N: **Coenzyme Q10.** In: *Product Monograph.* Therapeutic Research Center; 2017.
63. Medicines N: **Riboflavin.** In: *Product Monograph.* Therapeutic Research Center; 2017.
64. Roeder E: **Medicinal plants in Europe containing pyrrolizidine alkaloids.** *Die Pharmazie* 1995, **50**(2).
65. Chojkier M: **Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids.** *Journal of hepatology* 2003, **39**(3):437-446.
66. Program NT: **Chemical Information Review Document for Butterbur.** In. Research Triangle Park, NC: National Institutes of Health; 2009.
67. Medicines N: **Butterbur.** In: *Product Monograph.* Therapeutic Research Center; 2017.
68. WHO: **Pyrrolizidine Alkaloids Health and Safety Guide.** In. Geneva: World Health Organization; 1989.
69. Avula B, Wang YH, Wang M, Smillie TJ, Khan IA: **Simultaneous determination of sesquiterpenes and pyrrolizidine alkaloids from the rhizomes of Petasites hybridus (L.) G.M. et Sch. and dietary supplements using UPLC-UV and HPLC-TOF-MS methods.** *Journal of pharmaceutical and biomedical analysis* 2012, **70**:53-63.
70. Di Trapani G, Mei D, Marra C, Mazza S, Capuano A: **Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study.** *La Clinica terapeutica* 2000, **151**(3):145-148.
71. Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, Stacey B, Tepper S: **Efficacy of gabapentin in migraine prophylaxis.** *Headache* 2001, **41**(2):119-128.
72. Brandes JL, Poole A, Kallela M, Schreiber CP, MacGregor EA, Silberstein SD, Tobin J, Shaw R: **Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks.** *Cephalalgia : an international journal of headache* 2009, **29**(11):1133-1148.
73. Guilbert E, Boroditsky R, Black A, Kives S, Leboeuf M, Mirosh M, Senikas V, Wagner M-S, Weir E, York-Lowry J: **Canadian consensus guideline on continuous and extended hormonal contraception, 2007.** *Journal of Obstetrics and Gynaecology Canada* 2007, **29**(7):S1-S3.
74. Schwedt TJ: **Chronic migraine.** *BMJ : British Medical Journal* 2014, **348**.

75. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S *et al*: **Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.** *Headache* 2007, **47**(2):170-180.
76. Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F: **The effect of sodium valproate on chronic daily headache and its subgroups.** *The journal of headache and pain* 2008, **9**(1):37-41.
77. Saper JR, Lake AE, 3rd, Cantrell DT, Winner PK, White JR: **Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.** *Headache* 2002, **42**(6):470-482.
78. Negro A, Curto M, Lionetto L, Crialesi D, Martelletti P: **OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study.** *SpringerPlus* 2015, **4**(1):826.
79. Pharma A: **Elavil.** In: *Product Monograph.* Vaughan, ON; 2010.
80. Mylan Pharmaceuticals Inc: **Amitriptyline.** In: *FDA Monograph.* 2016.
81. Association CP: **Tricyclic Antidepressants.** In: *Product Monograph.* CPhA; 2016.
82. Purdy R: **Headache in Adults.** In: *RxTx.* Edited by RxTx C-: CPhA; 2017.
83. Regier L, Jensen B, Downey S: **Migraine: Agents for ACUTE/PROPHYLACTIC Treatment.** In: *RxFiles.* 2017.
84. McCormack J, Carleton B, Calissi P: **Dosage Adjustment in Renal Impairment.** In: *Therapeutics.* Edited by Jovaisas B. Ottawa (ON): Canadian Pharmacists Association; 2015.
85. Murphy E: **Acute pain management pharmacology for the patient with concurrent renal or hepatic disease.** *Anaesthesia and intensive care* 2005, **33**(3):311.
86. Dwyer JP, Jayasekera C, Nicoll A: **Analgesia for the cirrhotic patient: a literature review and recommendations.** *Journal of gastroenterology and hepatology* 2014, **29**(7):1356-1360.
87. Hrdina PD, Lapierre YD, Koranyi EK: **Altered amitriptyline kinetics in a depressed patient with porto-caval anastomosis.** *Canadian journal of psychiatry Revue canadienne de psychiatrie* 1985, **30**(2):111-113.
88. Morgan MH, Read AE: **Antidepressants and liver disease.** *Gut* 1972, **13**(9):697-701.
89. Inc. PC: **Effexor XR.** In: *Product Monograph.* 2016.
90. Wyeth Pharmaceuticals Inc: **Venlafaxine.** In: *FDA Monograph.* 2018.

91. Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S: **Dose adjustment in patients with liver disease**. *Drug safety* 2005, **28**(6):529-545.
92. Pharma B: **Epival**. In: *Product Monograph*. Etobicoke, ON; 2017.
93. AbbVie Inc: **Divalproex sodium**. In: *FDA Monograph*. 2017.
94. Lee M, Jensen B, Regier L: **Bipolar Disorder treatment chart**. In: *RxFiles drug comparison charts*. 7th edn. Saskatoon, SK: Saskatoon Health Region; 2016: 147-148.
95. Inc J: **Topamax**. In: *Product Monograph*. Toronto, ON; 2016.
96. Janssen Pharmaceuticals Inc: **Topiramate**. In: *FDA Monograph*. 2018.
97. Pharma B: **Depakene**. In: *Product Monograph*. Etobicoke, ON; 2017.
98. AbbVie Inc: **Valproic acid**. In: *FDA Monograph*. 2017.
99. AztraZeneca: **Atacand**. In: *Product Monograph*. Mississauga, ON; 2016.
100. Inc AP: **Candesartan**. In: *FDA Monograph*. 2018.
101. Canadian Pharmacists Association: **Angiotensin II Receptor Antagonists**. In: *CPhA Monograph*. Canadian Pharmacists Association; 2014.
102. Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, Hagen K: **A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study**. *Cephalalgia : an international journal of headache* 2014, **34**(7):523-532.
103. Canada M: **Prinivil**. In: *Product Monograph*. Kirkland, QC; 2017.
104. Almatica Pharma Inc: **Lisinopril**. In: *FDA Monograph*. 2017.
105. Canadian Pharmacists Association: **ACE Inhibitors**. In: *CPhA Monograph*. Canadian Pharmacists Association; 2011.
106. Pharmaceuticals N: **Lopresor**. In: *Product Monograph*. Dorval, QC; 2016.
107. Validus Pharmaceuticals: **Metoprolol**. In: *FDA Monograph*. 2017.
108. CPhA: **Beta-adrenergic blocking agents (CPhA)**. In: *Product Monograph*. CPhA; 2014.
109. Kangasniemi P, Andersen AR, Andersson PG, Gilhus NE, Hedman C, Hultgren M, Vilming S, Olesen J: **Classic migraine: effective prophylaxis with metoprolol**. *Cephalalgia : an international journal of headache* 1987, **7**(4):231-238.

110. Andersson PG, Dahl S, Hansen JH, Hansen PE, Hedman C, Kristensen TN, de Fine Olivarius B: **Prophylactic treatment of classical and non-classical migraine with metoprolol--a comparison with placebo.** *Cephalalgia : an international journal of headache* 1983, **3**(4):207-212.
111. Streng A, Linde K, Hoppe A, Pfaffenrath V, Hammes M, Wagenpfeil S, Weidenhammer W, Melchart D: **Effectiveness and tolerability of acupuncture compared with metoprolol in migraine prophylaxis.** *Headache* 2006, **46**(10):1492-1502.
112. Schellenberg R, Lichtenthal A, Wohling H, Graf C, Brixius K: **Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment?** *Headache* 2008, **48**(1):118-125.
113. Regardh CG, Jordo L, Ervik M, Lundborg P, Olsson R, Ronn O: **Pharmacokinetics of metoprolol in patients with hepatic cirrhosis.** *Clinical pharmacokinetics* 1981, **6**(5):375-388.
114. Canada P: **Inderal-LA.** In: *Product Monograph.* Kirkland, QC; 2016.
115. Canada T: **Teva-propranolol.** In: *Product Monograph.* Toronto, ON; 2011.
116. ANI Pharmaceuticals Inc: **Propranolol.** In: *FDA Monograph.* 2018.
117. Actavis Pharma Inc: **Propranolol** In: *FDA Monograph.* 2016.
118. Holroyd KA, Cottrell CK, O'Donnell FJ, Cordingley GE, Drew JB, Carlson BW, Himawan L: **Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial.** *BMJ (Clinical research ed)* 2010, **341**:c4871.
119. Shimell CJ, Fritz VU, Levien SL: **A comparative trial of flunarizine and propranolol in the prevention of migraine.** *South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde* 1990, **77**(2):75-77.
120. Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J: **Migraine prophylaxis. A comparison of propranolol and amitriptyline.** *Archives of neurology* 1987, **44**(5):486-489.
121. Canada T: **Teva-timolol.** In: *Product Monograph.* Toronto, ON; 2011.
122. Mylan pharmaceuticals Inc: **Timolol.** In: *FDA Monograph.* 2006.
123. Standnes B: **The prophylactic effect of timolol versus propranolol and placebo in common migraine: beta-blockers in migraine.** *Cephalalgia : an international journal of headache* 1982, **2**(3):165-170.

124. Lipton RB, Gobel H, Einhaupl KM, Wilks K, Mauskop A: **Petasites hybridus root (butterbur) is an effective preventive treatment for migraine**. *Neurology* 2004, **63**(12):2240-2244.
125. Diener HC, Rahlfs VW, Danesch U: **The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria**. *European neurology* 2004, **51**(2):89-97.
126. Database NP: **Ubiquinone**. In: *Lexicomp*. Lexicomp; 2017.
127. Ltd. JL: **Coq10**. In.; 2018.
128. J Schoenen JJ, M Lenaerts,: **Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial** *Neurology* 1998, **50**(2):466-470.
129. Canadian Pharmacists Association: **Vitamin B2 - Riboflavin (CPhA)**. In: *CPhA Monograph*. Canadian Pharmacists Association; 2017.
130. Pharmaceuticals E: **Frova**. In: *Product Monograph*. Chadds Ford, PA; 2012.
131. Endo pharmaceuticals Inc: **frovatriptan**. In: *FDA Monograph*. 2018.
132. Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E, Aube M, Leroux E, Becker WJ: **Canadian Headache Society Guideline: acute drug therapy for migraine headache**. *The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques* 2013, **40**(5 Suppl 3):S1-s80.
133. BGP Pharma ULC: **Epival (divalproex)**. In: *CA Product Monograph*. Etobicoke, Ontario; 2020.
134. AbbVie Inc: **Depakote ER (divalproex)**. In: *US Product Monograph*. North Chicago, IL; 2019.
135. Aurobindo Pharma Limited: **Divalproex sodium tablet, delayed release**. In: *US Product Monograph*. East Windsor, NJ; 2019.
136. BGP Pharma ULC: **Epival (divalproex)**. In: *CA Product Monograph*. Etobicoke, Ontario; 2021.
137. AbbVie Inc: **Depakote - Divalproex sodium**. In: *FDA Product Monograph*. North Chicago, IL; 2021.
138. **Adult Drug Book**. In.: University of Louisville, Division of Nephrology, Kidney Disease Program; 2020.
139. Mint Pharmaceuticals: **Mint-topiramate**. In: *CA Product Monograph*. Mississauga, ON; 2020.
140. Cipla USA: **Topiramate tablet**. In: *US Product Monograph*. Sunrise, FL; 2019.

141. Upsher-Smith Laboratories: **Topiramate extended-release capsules**. In: *US Product Monograph*. Denver, CO; 2019.
142. Auro Pharma: **Auro-Topiramate**. In: *CA Product Monograph*. Woodbridge, ON; 2020.
143. Janssen Pharmaceuticals Inc: **Topamax**. In: *US Product Monograph*. 2021.
144. Upsher-Smith Laboratories: **Qudexy XR (Topiramate extended-release)**. In: *US Product Monograph*. Denver, CO; 2020.
145. Pro Doc: **Candesartan**. In: *CA Product Monograph*. Laval, Quebec; 2021.
146. Alembic Pharmaceuticals Inc.: **Candesartan cilexetil**. In: *US Product Monograph*. Bridgewater, NJ; 2021.
147. Corporation JP: **Jamp-candesartan**. In: *CA Product Monograph*. Boucherville, QC; 2020.
148. Alembic Pharmaceuticals Inc.: **Candesartan cilexetil**. In: *US Product Monograph*. Bridgewater, NJ; 2020.
149. **Adult Drug Book** In.: University of Louisville, Division of Nephrology, Kidney Disease Program; 2021.
150. Corporation JP: **Jamp-Candestartan - candesartan cilexetil**. In: *Product Monograph*. Boucherville, QC: Jamp Pharma Corporation; 2018.
151. ANI Pharmaceuticals: **Atacand (candesartan)**. In: *US Product Monograph*. Baudette, MN: AstraZeneca; 2018.
152. Rxtx: **Angiotensin II receptor antagonists**. In: *CPhA monograph*. 2014.
153. Ezekowitz JA, O'Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, Giannetti N, Grzeslo A, Hamilton PG, Heckman GA *et al*: **2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure**. *The Canadian journal of cardiology* 2017, **33**(11):1342-1433.
154. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM *et al*: **2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America**. *Circulation* 2017.
155. de Denus S, White M: **Heart Failure**. In: *RxTx*. 2018.
156. Jin M, Jensen B, Regier L: **Heart Failure (HF): Treatment Overview/Drug and Dosage Considerations**. In: *RxFiles*. Saskatoon Health Region; 2018.

157. Pharmascience Inc: **Pms-metoprolol-I**. In: *Canadian Product Monograph*. Montreal, QC; 2020.
158. Novartis Pharmaceuticals Canada Inc.: **LOPRESOR (metoprolol tartrate)**. In: *CA Product Monograph*. Dorval, QC; 2020.
159. Youngtech Pharmaceuticals Inc.: **Metoprolol tartrate tablet**. In: *US Product Monograph*. Cranbury, NJ; 2020.
160. BluePoint Laboratories: **Metoprolol succinate ER tablets**. In: *US Product Monograph*. Springdale, AR; 2021.
161. Sun Pharmaceutical Industries Inc.: **Metoprolol succinate capsule extended release**. In: *US Product Monograph*. New Brunswick, NJ; 2020.
162. Aralez Pharmaceuticals US Inc: **Torprol XL (metoprolol succinate)**. In: *US Product Monograph*. Parsippany, NJ; 2019.
163. Validus Pharmaceuticals LLC: **Lopressor (metoprolol tartrate)**. In: *US Product Monograph*. Parsippany, NJ; 2019.
164. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ *et al*: **Pharmacogenetics: from bench to byte--an update of guidelines**. *Clin Pharmacol Ther* 2011, **89**(5):662-673.
165. **Dutch Guidelines**. [<https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf>]
166. Inc. NPC: **Lopressor - metoprolol tartrate**. In: *Product Monograph*. Dorval, Quebec: Novartis Pharmaceuticals Canada Inc.; 2016.
167. solutions Ap: **Metoprolol Succinate (Toprol XL) ER** In: *Product Monograph*. Cookerville, TN: Aphenia pharma solutions; 2018.
168. Aralez Pharmaceuticals US Inc: **TOPROL-XL (metoprolol succinate)**. In: *US Product Monograph*. Princeton, NJ: Aralez Pharmaceuticals US Inc; 2016.
169. Rxtx: **Beta-adrenergic Blocking Agents**. In: *CPhA monograph*. 2018.
170. Pfizer Canada ULC: **INDERAL-LA (Propranolol Hydrochloride Extended-Release Capsules)**. In: *CA Product Monograph*. Kirkland, QC; 2021.
171. Teva Canada Limited: **Teva-propranolol**. In: *CA Product Monograph*. Toronto, ON; 2011.

172. Amneal Pharmaceuticals NY LLC: **Propranolol hydrochloride tablet**. In: *US Product Monograph*. Bridgewater, NJ; 2021.
173. ANI Pharmaceuticals Inc.: **INDERAL LA (propranolol hydrochloride capsule extended release)**. In: *US Product Monograph*. Baudette, MN; 2020.
174. AA Pharma Inc.: **Timolol maleate tablets**. In: *CA Product Monograph*. Vaughan, ON; 2018.
175. Trigen Laboratories LLC: **Timolol maleate tablet**. In: *US Product Monograph*. Bridgewater, NJ; 2021.
176. Novartis Pharmaceuticals Canada Inc.: **Aimovig (erenumab injection)**. In: *CA Product Monograph*. Dorval, QC; 2021.
177. Amgen Inc: **Aimovig (erenumab injection)**. In: *US Product Monograph*. Thousand Oaks, CA; 2021.
178. Teva Canada Limited: **Ajovy (Fremanezumab)**. In: *CA Product Monograph*. Toronto, ON; 2021.
179. teva Pharmaceuticals USA Inc: **Ajovy - fremanezumab**. In: *US Product Monograph*. 2021.
180. Eli Lilly Canada inc: **Emgality (Galcanezumab)**. In: *CA Product Monograph*. Toronto, ON; 2020.
181. Eli Lilly and Company: **Emgality - galcanezumab**. In: *US Product Monograph*. 2021.
182. Lundbeck Pharmaceuticals: **Vyepti (Eptinezumab-jjmr injection)**. In: *US Product Monograph*. Bothell, WA; 2021.
183. Angita Pharma Inc: **AG-Amitriptyline**. In: *CA Product Monograph*. Boucherville, QC; 2021.
184. Upsher-Smith Laboratories: **Amitriptyline hydrochloride**. In: *US Product Monograph*. Maple Grove, MN; 2021.
185. Apotex Inc: **Apo-amitriptyline**. In: *CA Product Monograph*. Toronto, ON; 2019.
186. Mylan Pharmaceuticals: **Amitriptyline**. In: *US Product Monograph*. Morgantown, WV; 2016.
187. VA/DoD The Management of Major Depressive Disorder Working Group: **VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder**. In. Online: Department of Veterans Affairs, Department of Defense; 2016.
188. Hedayati SS, Yalamanchili V, Finkelstein FO: **A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease**. *Kidney international* 2012, **81**(3):247-255.

189. Nagler EV, Webster AC, Vanholder R, Zoccali C: **Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP)**. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association* 2012, **27**(10):3736-3745.
190. Marcan Pharmaceuticals Inc: **Mar-amitriptyline**. In: *CA Product Monograph*. Ottawa, ON; 2020.
191. Accord Healthcare Inc: **Amitriptyline hydrochloride**. In: *US Product Monograph*. Durham, NC; 2019.
192. Mullish BH, Kabir MS, Thursz MR, Dhar A: **Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation**. *Alimentary pharmacology & therapeutics* 2014, **40**(8):880-892.
193. Murphy EJ: **Acute pain management pharmacology for the patient with concurrent renal or hepatic disease**. *Anaesth Intensive Care* 2005, **33**(3):311-322.
194. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A *et al*: **Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update**. *Clin Pharmacol Ther* 2017, **102**(1):37-44.
195. Mu A, Weinberg E, Moulin DE, Clarke H: **Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement**. *Can Fam Physician* 2017, **63**(11):844-852.
196. Bates D, Schultheis BC, Hanes MC, Jolly SM, Chakravarthy KV, Deer TR, Levy RM, Hunter CW: **A Comprehensive Algorithm for Management of Neuropathic Pain**. *Pain Med* 2019, **20**(Suppl 1):S2-S12.
197. Sumitani M, Sakai T, Matsuda Y, Abe H, Yamaguchi S, Hosokawa T, Fukui S: **Executive summary of the Clinical Guidelines of Pharmacotherapy for Neuropathic Pain: second edition by the Japanese Society of Pain Clinicians**. *J Anesth* 2018, **32**(3):463-478.
198. Teva Canada Limited: **Act-Venlafaxine**. In: *CA Product Monograph*. Toronto, ON; 2021.
199. Wyeth Pharmaceuticals Inc: **Effector XR - Venlafaxine hydrochloride**. In: *US Product Monograph*. 2021.
200. Pfizer_Canada: **EFFEXOR_XR_(venlafaxine_xr)**. In: *Product Monograph*. Kirkland, QC: Pfizer_Canada; 2018.
201. Canadian_Pharmacists_Association: **Dosage Adjustment in Renal Impairment**. In: *Therapeutics*. Ottawa, Ontario: Canadian_Pharmacists_Association; 2018.

202. Pfizer Canada: **Effexor XR**. In: *CA Product Monograph*. Kirkland, QC; 2020.
203. PD-Rx Pharmaceuticals: **Effexor XR**. In: *US Product Monograph*. Oklahoma City, OK; 2020.
204. Pfizer_Wyeth_USA: **EFFEXOR_XR_(venlafaxine_xr)US**. In: *Product Monograph*. Philadelphia, PA: Pfizer; 2017.
205. National_Institutes_of_Health(USA): **VENLAFAXINE_LiverTox**. In: *LiverTox*. Bethesda, MD: U.S. National Library of Medicine; 2018.
206. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong K, Sangkuhl CF, Thorn CF, Altman RB, Klein TE: **Pharmacogenomics Knowledge for Personalized Medicine**. *Clinical Pharmacology & Therapeutics* 2012, **92**(4):414-417.
207. APOTEX INC: **Apo-atenolol**. In: *CA Product Monograph*. Toronto, ON; 2021.
208. Unichem Pharmaceuticals (USA) Inc: **Atenolol**. In: *US Product Monograph*. East Brunswick, NJ; 2021.
209. AstraZeneca Canada Inc: **Tenormin (atenolol)**. In: *CA Product Monograph*. Mississauga, ON; 2020.
210. Almatica Pharma LLC: **Tenormin (atenolol)**. In: *US Product Monograph*. Morristown, NJ; 2019.
211. Division of Nephrology & Hypertension: **Adult Drug Book**. In. Louisville, KY: University of Louisville, Division of Nephrology, Kidney Disease Program; 2020.
212. Almatica Pharma Inc: **Tenormin**. In: *US Product Monograph*. Pine Brook, NJ: Almatica Pharma Inc,; 2017.
213. Munar MY, Singh H: **Drug dosing adjustments in patients with chronic kidney disease**. *Am Fam Physician* 2007, **75**(10):1487-1496.
214. Canadian Pharmacists Association: **Beta-adrenergic Blocking agents**. In: *CPhA Monograph*. Canadian Pharmacists Association; 2014.
215. Committee) GGaPaA: **Atrial Fibrillation- Diagnosis and Management**. In., April 1, 2015 edn. GPAC (Guidelines and Protocols and Advisory Committee); 2015.
216. Apotex INC: **Apo-nadolol**. In: *CA Product Monograph*. Toronto, ON; 2020.
217. US Worldmeds LLC: **Corgard (nadolol)**. In: *US Product Monograph*. Louisville, KY; 2021.

218. Ryan RE, Sr., Ryan RE, Jr., Sudilovsky A: **Nadolol: its use in the prophylactic treatment of migraine.** *Headache* 1983, **23**(1):26-31.
219. US Worldmeds LLC: **Corgard (nadolol).** In: *US Product Monograph.* Louisville, KY; 2020.
220. Fallo F, Gregianin M, Bui F, Macri C, Folino P, Mantero F: **Comparison of the antihypertensive and renal effects of tertatolol and nadolol in hypertensive patients with mild renal impairment.** *European journal of clinical pharmacology* 1991, **40**(3):309-311.
221. Searchlight Pharma Inc.: **Zestril (lisinopril).** In: *CA Product Monograph.* Montreal, QC; 2021.
222. Camber Pharmaceuticals Inc: **Lisinopril.** In: *US Product Monograph.* Piscataway, NJ; 2021.
223. Teva Canada Limited: **Teva-lisinopril.** In: *CA Product Monograph.* Toronto, ON; 2019.
224. AstraZeneca Canada Inc: **Zestril (lisinopril).** In: *CA Product Monograph.* Mississauga, ON; 2017.
225. Almatica Pharma LLC: **Zestril (lisinopril).** In: *US Product Monograph.* Morristown, NJ; 2020.
226. Mosley JD, Shaffer CM, Van Driest SL, Weeke PE, Wells QS, Karnes JH, Velez Edwards DR, Wei WQ, Teixeira PL, Bastarache L *et al*: **A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough.** *The pharmacogenomics journal* 2016, **16**(3):231-237.
227. Hallberg P, Persson M, Axelsson T, Cavalli M, Norling P, Johansson HE, Yue QY, Magnusson PK, Wadelius C, Eriksson N *et al*: **Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population.** *Pharmacogenomics* 2017, **18**(3):201-213.
228. Inc. SC: **Sandoz Lisinopril.** In: *Product Monograph.* Boucherville, QC, Canada: Sandoz Canada Inc.; 2018.
229. Almatica Pharma Inc: **Zestril (lisinopril).** In: *US Product Monograph.* Pine Brook, NJ: Almatica Pharma Inc; 2017.
230. Rxtx: **ACE Inhibitors-CPhA Monograph.** In.: CPhA; 2011.
231. Teva Canada Limited: **Act Memantine.** In: *CA Product Monograph.* Toronto, Ontario; 2020.
232. Amneal Pharmaceuticals: **Memantine hydrochloride extended release.** In: *US Product Monograph.* 2020.
233. Alembic Pharmaceuticals Inc: **Memantine Hydrochloride.** In: *US Product Monograph.* 2021.



234. Sivem Pharmaceuticals ULC: **Sivem memantine**. In: *CA Product Monograph*. Saint-Laurent, Quebec; 2018.
235. Allergan USA Inc: **Namenda (memantine)**. In: *US Product Monograph*. Madison, NJ; 2018.
236. Allergan USA Inc: **Namenda XR (memantine)**. In: *US Product Monograph*. Madison, NJ; 2018.